Quidel 产品代理
Quidel 产品代理
Quidel于1979年开始运营，并于1983年推出了第一批产品。从那时起，Quidel通过内部开发和收购扩大了产品基础，重点是加大研发力度，加快新产品推出速度。我们的核心竞争力和能力包括免疫分析开发、自动化制造、单克隆抗体表征和开发以及分子分析开发。我们目前的产品大致分为以下几类：（1）横向流动，我们是传染病和生殖健康领域的市场领导者；（2） 直接荧光抗体（DFA），具有传染病和病毒学方面的专业知识；（3） 微量滴度生产，重点关注骨骼和补体途径市场；（4） 荧光免疫分析产品（Sofia）；（5）分子诊断产品，包括世界上第一款经FDA批准的手持分子设备AmpliVue。作为强大产品线的一部分，其他分子和Sofia测试目前正在开发或临床试验中。
Molecular Diagnostics
Helicase Dependent Amplification Assays
Real-time RT-PCR Assays
Instrumentation
Controls & Supplies
Immunoassays
Fluorescent Immunoassays
Rapid Test Kits
ELISA Immunoassays
Instrumentation
Controls & Supplies
DHI Cell Culture & Fluorescent Tests
Cell Culture & Cell Lines
Fluorescent Antibody Kits & Reagents
Media & Culture Solutions
Research
Cancer Research Products
Inflammatory & Autoimmune
Metabolic Syndrome
Osteoporosis (Bone Health)
Quidel Corporation (Nasdaq: QDEL) is a California-based leading diagnostic healthcare manufacturer serving to enhance the health and well-being of people around the globe through the development of diagnostic solutions that can lead to improved patient outcomes and provide economic benefits to the healthcare system.
Quidel commenced operations in 1979 and launched its first products in 1983. Since that time, Quidel has expanded its product base through internal development and acquisition with a focus on increasing its research and development efforts to accelerate the rate of new product introductions. Our core competencies and capabilities include immunoassay development, automated manufacturing, monoclonal antibody characterization and development, and molecular assay development. Our current products fall generally into these categories: (1) lateral flow, where we are market leaders in infectious disease and reproductive health; (2) direct fluorescent antibodies (DFA), with expertise in infectious disease and virology; (3) micro-titer production, with a focus on bone and complement pathway markets; (4) fluorescent immunoassay products (Sofia); and (5) molecular diagnostic products including the world’s first FDA-cleared handheld molecular device, AmpliVue. Additional molecular and Sofia tests are currently in development or in clinical trials as part of a robust product pipeline.
Whether at our headquarters in San Diego, California, at our research and manufacturing operations in Ohio, Massachusetts, or in Germany, or through our Commercial organization around the world, Quidel is delivering a continuum of diagnostic solutions from advanced lateral-flow and direct fluorescent antibody to molecular diagnostic tests that further improve the quality of healthcare.
